BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL

Nicox Investor & Media Contact:
Gavin Spencer
[e-mail]
[phone]

Mary-Ann Chang
[e-mail]
[phone]

Nicox Media France Contact:
Sophie Baumont
[e-mail]
[phone]

Bausch Health Investor Contact:
Art Shannon
[e-mail]
[phone]
[phone] (toll free)

                Bausch Health Media Contact:
Lainie Keller
[e-mail]
 [phone]

 

                                                                               

BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL

SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária).

VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.¹

“The approval of VYZULTA in Brazil marks its tenth regulatory approval. We will continue to focus our efforts on securing additional regulatory approvals for this important treatment option for people suffering from glaucoma to help address this critical unmet medical need,” said Thomas J. Appio, president, Bausch + Lomb/International.

VYZULTA is now approved in 10 markets, including Argentina, Brazil, Canada, Colombia, Hong Kong, Mexico, South Korea, Taiwan, Ukraine and the United States.

Indication and Important Safety Information about VYZULTA

INDICATION AND USAGE
VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.